173 related articles for article (PubMed ID: 8733065)
1. Cardiac adrenergic receptor effects of carvedilol.
Yoshikawa T; Port JD; Asano K; Chidiak P; Bouvier M; Dutcher D; Roden RL; Minobe W; Tremmel KD; Bristow MR
Eur Heart J; 1996 Apr; 17 Suppl B():8-16. PubMed ID: 8733065
[TBL] [Abstract][Full Text] [Related]
2. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes.
Asano K; Zisman LS; Yoshikawa T; Headley V; Bristow MR; Port JD
J Cardiovasc Pharmacol; 2001 Jun; 37(6):678-91. PubMed ID: 11392464
[TBL] [Abstract][Full Text] [Related]
3. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
Maack C; Cremers B; Flesch M; Höper A; Südkamp M; Böhm M
Br J Pharmacol; 2000 Jul; 130(5):1131-9. PubMed ID: 10882399
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
Molenaar P; Christ T; Ravens U; Kaumann A
Cardiovasc Res; 2006 Jan; 69(1):128-39. PubMed ID: 16225854
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
Bristow MR; Larrabee P; Müller-Beckmann B; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD
Clin Investig; 1992; 70 Suppl 1():S105-13. PubMed ID: 1350478
[TBL] [Abstract][Full Text] [Related]
6. Receptor pharmacology of carvedilol in the human heart.
Bristow MR; Larrabee P; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port JD; Müller-Beckmann B
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S68-80. PubMed ID: 1378154
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes.
Flesch M; Ettelbrück S; Rosenkranz S; Maack C; Cremers B; Schlüter KD; Zolk O; Böhm M
Cardiovasc Res; 2001 Feb; 49(2):371-80. PubMed ID: 11164847
[TBL] [Abstract][Full Text] [Related]
8. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Ahmed A
Eur J Heart Fail; 2003 Dec; 5(6):709-15. PubMed ID: 14675848
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Molenaar P; Christ T; Berk E; Engel A; Gillette KT; Galindo-Tovar A; Ravens U; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):629-40. PubMed ID: 24668024
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
Qvigstad E; Sjaastad I; Bøkenes J; Schiander I; Solberg L; Sejersted OM; Osnes JB; Skomedal T
Eur J Pharmacol; 2005 May; 516(1):51-9. PubMed ID: 15916756
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol blockade of rat myocardial alpha1-adrenoceptors.
Qvigstad E; Osnes JB; Sandnes D; Schiander I; Bøkenes J; Sjaastad I; Skomedal T
Eur J Pharmacol; 2003 Nov; 481(1):83-9. PubMed ID: 14637179
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR
J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol binding to β2-adrenergic receptors inhibits CFTR-dependent anion secretion in airway epithelial cells.
Peitzman ER; Zaidman NA; Maniak PJ; O'Grady SM
Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(1):L50-8. PubMed ID: 26566905
[TBL] [Abstract][Full Text] [Related]
14. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
Willette RN; Mitchell MP; Ohlstein EH; Lukas MA; Ruffolo RR
Pharmacology; 1998 Jan; 56(1):30-6. PubMed ID: 9467185
[TBL] [Abstract][Full Text] [Related]
16. Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy.
Böhm M; Ettelbrück S; Flesch M; van Gilst WH; Knorr A; Maack C; Pinto YM; Paul M; Teisman AC; Zolk O
Cardiovasc Res; 1998 Oct; 40(1):146-55. PubMed ID: 9876327
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H
Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575
[TBL] [Abstract][Full Text] [Related]
18. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
[TBL] [Abstract][Full Text] [Related]
19. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.
Maack C; Tyroller S; Schnabel P; Cremers B; Dabew E; Südkamp M; Böhm M
Br J Pharmacol; 2001 Apr; 132(8):1817-26. PubMed ID: 11309254
[TBL] [Abstract][Full Text] [Related]
20. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
